Skip to main content
ACTU
NASDAQ Life Sciences

FDA Clears IND for Oral Elraglusib, Paving Way for New Cancer Drug Study

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.47
Mkt Cap
$78.243M
52W Low
$1.58
52W High
$11.99
52W Position info
120% above low
Off High info
71% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ACTU has more than doubled off its 52-week low of $1.58.

Summary

Actuate Therapeutics announced FDA Investigational New Drug (IND) clearance for its oral formulation of elraglusib, enabling the company to initiate a Phase 1/2 study. This strategic move prioritizes an oral tablet designed for enhanced patient convenience, broader clinical utility, and improved drug exposure, building on positive Phase 2 data from the IV formulation in metastatic pancreatic cancer. This development is a critical positive catalyst for Actuate, especially given its recent 10-K filing which included a going concern warning with cash expected to last only until July 2026. Advancing its lead asset with a potentially superior formulation is vital for the company's long-term viability and ability to attract future funding or partnerships. Investors should monitor the initiation and progress of the Phase 1/2 study, expected in the second half of 2026, and any subsequent financing activities.

At the time of this announcement, ACTU was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.2M. The 52-week trading range was $1.58 to $11.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ACTU - Latest Insights

ACTU
Nov 13, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.2853
Real-time Price: $0.2601 info
Change: -$0.0252 (-9%) info
Market Cap: $15.192M info
ACTU
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2853
Real-time Price: $0.2601 info
Change: -$0.0252 (-9%) info
Market Cap: $15.192M info
ACTU
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3351
Real-time Price: $0.2601 info
Change: -$0.075 (-22%) info
Market Cap: $15.192M info
ACTU
Oct 28, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3833
Real-time Price: $0.2601 info
Change: -$0.1232 (-32%) info
Market Cap: $15.192M info
ACTU
Oct 28, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.2601 info
Change: -$0.1099 (-30%) info
Market Cap: $15.192M info